GEN Exclusives

More »

GEN News Highlights

More »
Feb 20, 2009

Cordex Pharma Taps Cato to Undertake  Clinical Research

  • Cordex Pharma has employed Cato BioVentures to perform regulatory services and oversight of clinical testing of its products.

    Under the agreement, a portion of Cato's compensation for rendered services will be in the form of Cordex equity.

    Initially, the collaboration will focus on Cordex' Phase III trial with ATPace for the treatment of paroxysmal supraventricular tachycardia (PSVT). ATPace is a stable formulation of adenosine 5'-triphosphate administered by intravenous injection for the acute termination of PSVT.



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Children and Antipsychotic Drugs

Do you think children and adolescents with behavioral problems are overmedicated?